
Perfuze Receives FDA 510(k) Clearance for NeuroSheath, Completing Its Comprehensive Stroke Thrombectomy System
Perfuze, a neurovascular medical device company focused on developing technologies for the treatment of stroke, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for NeuroSheath™, an 8 French (8F) long sheath specifically developed for neurovascular access procedures.
The FDA clearance represents an important milestone in Perfuze’s efforts to expand its neurovascular product portfolio and strengthen its position in the mechanical thrombectomy market. NeuroSheath completes the company’s stroke thrombectomy system by providing an access solution designed to work alongside its aspiration catheters and other neurovascular devices.
The newly cleared sheath is designed to accommodate large-bore aspiration catheters, including Perfuze’s Millipede88® aspiration catheter, which features a 0.088-inch internal diameter and is built using the company’s patented Corrugated™ technology.
With NeuroSheath, Perfuze aims to provide physicians with a more comprehensive procedural solution that supports the entire thrombectomy workflow, from vascular access to clot removal.
The company plans to begin a limited market release of NeuroSheath at selected stroke centers across the United States. Following this initial introduction, Perfuze expects to make the device fully available in the U.S. market in 2027.
The development is intended to address an important requirement in mechanical thrombectomy procedures: providing physicians with an access sheath capable of accommodating larger aspiration catheters without compromising the flexibility and maneuverability needed to navigate complex vascular anatomy.
NeuroSheath Completes Perfuze’s Stroke Thrombectomy Portfolio
Mechanical thrombectomy is an important treatment approach for selected patients experiencing acute ischemic stroke caused by the blockage of a large blood vessel in the brain.
During the procedure, physicians use specialized catheter-based devices to reach the blocked artery and remove the blood clot responsible for restricting blood flow. Restoring circulation to the affected area of the brain as quickly as possible is a central objective of the intervention.
The procedure requires several interconnected medical devices, including access sheaths, guide catheters, aspiration catheters, and other supporting technologies.
Each component plays a role in enabling physicians to navigate the vascular system, reach the target location, and remove the clot.
NeuroSheath has been developed to address the vascular access component of this treatment process. It is designed to provide an entry pathway through which other devices, including large-bore aspiration catheters, can be introduced during the procedure.
The addition of NeuroSheath completes Perfuze’s broader thrombectomy portfolio, which already includes the Millipede88 and Millipede70 aspiration catheters, together with the corresponding Zipline88 and Zipline70 access catheters.
By bringing these products together, the company aims to provide physicians with a coordinated system designed to support different stages of mechanical thrombectomy.
The system is intended to offer flexibility in selecting aspiration catheter sizes based on the requirements of individual procedures.
This is particularly relevant because the anatomy of the patient’s vascular system, the location of the blockage, and the characteristics of the clot can influence the devices physicians choose to use.
With NeuroSheath, Perfuze aims to provide an access solution that supports the use of larger aspiration catheters while maintaining the maneuverability required for neurovascular procedures.
8F Design Supports Large-Bore Aspiration Catheters
One of the central features of NeuroSheath is its 8 French design, which allows it to accommodate aspiration catheters up to 8F in size.
The diameter of an access sheath is an important consideration in mechanical thrombectomy because the sheath serves as the entry pathway for the other devices used during the procedure.
Every catheter introduced into the vascular system must pass through this access point. Consequently, the size and internal capacity of the sheath can influence which aspiration catheters a physician can use.
Larger aspiration catheters, commonly described as super-bore catheters, generally require an 8F long sheath.
However, many physicians have historically been more familiar with 6F systems. Moving to a larger sheath can introduce additional considerations involving ease of use, navigation, and maneuverability.
Perfuze developed NeuroSheath to address these requirements by combining the capacity needed for larger aspiration catheters with design features intended to support navigation through challenging vascular anatomy.
The sheath is specifically designed to accommodate the company’s Millipede88 aspiration catheter, which has a 0.088-inch internal diameter.
This compatibility is important because larger aspiration catheters are designed to provide a substantial pathway for clot aspiration during mechanical thrombectomy.
The ability to use a larger catheter may provide physicians with additional procedural options when selecting devices for individual patients.
NeuroSheath is intended to ensure that the access component does not unnecessarily restrict the catheter choices available to physicians.
Designed for Challenging Neurovascular Anatomy
Beyond its ability to accommodate larger aspiration catheters, NeuroSheath has been developed with an emphasis on maneuverability.
Navigating the vascular system during neurovascular procedures can be challenging because patients have different anatomical characteristics. Physicians must guide devices through blood vessels while managing variations in vessel curvature, branching patterns, and vascular access pathways.
One example is a Type III aortic arch, which can present additional navigation challenges during procedures involving access through the arterial system.
The ability to navigate challenging anatomy is an important consideration when selecting an access sheath for mechanical thrombectomy.
Perfuze designed NeuroSheath to combine the larger internal capacity required for super-bore aspiration catheters with the maneuverability needed for these complex anatomical situations.
The company aims to make the transition from conventional 6F access systems to larger 8F systems more seamless for physicians.
By supporting aspiration catheters up to 8F, including Millipede88, NeuroSheath is intended to provide greater flexibility in procedural planning.
Rather than allowing the limitations of the access sheath to determine which catheter can be selected, the system is designed to give physicians more freedom to choose an appropriate aspiration catheter based on the specific requirements of each case.
This approach is intended to make the procedure more adaptable to individual patient anatomy and physician preferences.
Physicians Highlight the Importance of Greater Catheter Flexibility
Sunil Sheth, MD, Director of the Vascular and Interventional Neurology Division in the Department of Neurology at UTHealth Houston, highlighted the importance of access sheath compatibility when selecting aspiration catheters for stroke thrombectomy.
According to Sheth, NeuroSheath is designed to provide physicians with the versatility and flexibility to use aspiration catheters of different sizes, including super-bore catheters measuring up to 0.088 inches.
He emphasized that the objective is to allow the specific requirements of each procedure to determine the catheter selection rather than having the available sheath size restrict the physician’s options.
Sheth explained that this is the type of flexibility physicians have been seeking in a long sheath designed specifically for neurovascular access.
His comments highlight an important consideration in thrombectomy device development. Although aspiration catheters receive considerable attention because of their role in removing clots, the supporting access system is equally important in enabling physicians to use those devices effectively.
A sheath that cannot accommodate a particular catheter may limit procedural options, making compatibility an important factor when developing integrated thrombectomy systems.
NeuroSheath is intended to address this requirement by providing an access platform designed around the needs of modern large-bore aspiration technology.
Perfuze Focuses on Delivering a Complete Thrombectomy Solution
Wayne Allen, CEO of Perfuze, described the FDA clearance as a significant development in the company’s efforts to complete its stroke thrombectomy product portfolio.
He explained that every mechanical thrombectomy procedure begins with vascular access and that NeuroSheath extends the company’s product offering from the clot-removal stage in the brain back to the access point in the groin, where the procedure begins.
According to Allen, the addition of NeuroSheath provides physicians with a more complete stroke treatment system in which the different components are designed to work together.
He also outlined the company’s next priorities following the regulatory milestone.
Perfuze plans to focus on performing its first U.S. clinical cases using the newly cleared device before progressing toward a broader commercial launch in 2027.
The limited market release at selected U.S. stroke centers will provide the initial pathway for introducing NeuroSheath into clinical practice.
This phased introduction will precede the company’s anticipated full U.S. market availability.
The strategy reflects Perfuze’s focus on expanding its commercial presence while introducing a complete portfolio of neurovascular access and aspiration technologies.
Millipede88 Demonstrates Clinical Performance in the MARRS Pivotal Study
NeuroSheath joins Perfuze’s existing Millipede88 and Millipede70 aspiration catheters, along with the corresponding Zipline88 and Zipline70 access catheters.
Among these products, Millipede88 represents an important component of the company’s large-bore aspiration technology portfolio.
The catheter is built using Perfuze’s patented Corrugated technology and is designed to support aspiration-based clot removal during mechanical thrombectomy.
The company also highlighted findings from its MARRS pivotal study, in which Millipede88 achieved near-complete or complete reperfusion, defined as modified Thrombolysis in Cerebral Infarction (mTICI) grade 2c or better, on the first pass in 75% of M1 occlusions treated using direct aspiration.
M1 occlusions involve blockage of the M1 segment of the middle cerebral artery, an important blood vessel supplying large portions of the brain.
Reperfusion refers to the restoration of blood flow to tissue following an obstruction.
The mTICI grading system is commonly used in stroke intervention studies to assess the degree of blood flow restoration following endovascular treatment.
An mTICI score of 2c or better represents near-complete or complete reperfusion, indicating a high degree of restoration of blood flow in the affected vascular territory.
First-pass reperfusion is an important procedural outcome because it evaluates whether the desired level of blood flow restoration is achieved following the initial device pass without requiring additional attempts.
The 75% result reported by Perfuze in the MARRS pivotal study provides clinical performance information supporting the development of its Millipede88 aspiration catheter.
The company is positioning NeuroSheath as a complementary access technology that enables physicians to use Millipede88 as part of a more integrated thrombectomy system.
Expanding Access Technology for Mechanical Thrombectomy
The development of NeuroSheath reflects the broader evolution of neurovascular devices designed to improve the flexibility and efficiency of endovascular stroke procedures.
Mechanical thrombectomy has become an important treatment option for selected patients with acute ischemic stroke caused by large-vessel occlusions.
As neurovascular technologies continue to advance, device developers are focusing on improving catheter design, aspiration capabilities, vascular access, and the ability to navigate complex anatomy.
Large-bore aspiration catheters are one area of development, with manufacturers working to provide physicians with devices designed to support clot removal through aspiration.
However, the effectiveness of a complete thrombectomy system also depends on the supporting access technologies.
A coordinated system must allow physicians to introduce the required devices, navigate the vascular pathway, and reach the target location while accommodating different patient anatomies.
Perfuze’s approach brings together its aspiration catheters and access technologies within a broader product portfolio.
The addition of NeuroSheath strengthens this strategy by addressing the access requirements associated with larger aspiration catheters.
U.S. Market Introduction Planned Ahead of Full 2027 Launch
Following the FDA 510(k) clearance, Perfuze will begin a limited market release of NeuroSheath at selected stroke centers in the United States.
The initial release will allow the company to begin introducing the product to healthcare facilities and physicians involved in neurovascular procedures.
Perfuze expects full U.S. commercial availability in 2027.
The company will initially focus on completing its first U.S. cases before moving toward the wider market launch.
This phased commercial strategy represents the next stage in the development of Perfuze’s integrated stroke thrombectomy portfolio.
With NeuroSheath now FDA-cleared, the company has added an important access component to its existing aspiration and catheter technologies.
The combination of NeuroSheath, Millipede88, Millipede70, Zipline88, and Zipline70 is designed to provide physicians with a coordinated selection of devices supporting different aspects of mechanical thrombectomy.
Ultimately, Perfuze aims to give neurovascular specialists greater flexibility in selecting access and aspiration technologies according to the specific requirements of each stroke procedure.
The FDA clearance of NeuroSheath marks a significant milestone in that strategy, bringing the company’s vision of a complete stroke thrombectomy system closer to broader clinical and commercial adoption.
About Perfuze
Perfuze® is a medical device company headquartered in Galway, Ireland, dedicated to developing next-generation catheter-based aspiration technology for acute ischemic stroke. Its growing neurovascular portfolio, including the Millipede88® and Millipede70® Aspiration Catheters, the Zipline Access Catheters and the NeuroSheath™ 8F Long Sheath, supports physicians from neurovascular access through to aspiration.


